Design Therapeutics (DSGN) Free Cash Flow (2020 - 2026)

Design Therapeutics has disclosed Free Cash Flow across 7 years of filings, most recently posting -$16.4 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$16.4 million, up 2.55% year-over-year; the trailing twelve-month figure through Mar 2026 was -$54.1 million (down 13.53% YoY), and the FY2025 annual result was -$54.6 million, down 25.56% from the prior year.
• Free Cash Flow came in at -$16.4 million for Q1 2026 at Design Therapeutics, down from -$12.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$9.5 million in Q3 2024 to a low of -$17.5 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$12.8 million (2023), against an average of -$13.3 million.
• Across the five-year window, Free Cash Flow tumbled 217.59% in 2022 and jumped 34.67% in 2024, its largest moves.
• Design Therapeutics' Free Cash Flow stood at -$15.4 million in 2022, then increased by 16.61% to -$12.8 million in 2023, then advanced by 23.12% to -$9.9 million in 2024, then slipped by 21.7% to -$12.0 million in 2025, then sank by 36.93% to -$16.4 million in 2026.
• The last three Free Cash Flow figures came in at -$16.4 million (Q1 2026), -$12.0 million (Q4 2025), and -$11.2 million (Q3 2025), per Business Quant data.